Status:
UNKNOWN
The Low HDL On Six Weeks Statin Therapy (LOW) Study
Lead Sponsor:
Craigavon Area Hospital
Conditions:
HDL Cholesterol
Coronary Arteriosclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Abnormal blood cholesterol levels increase the risk of developing, or dying from heart disease. It is well recognised that if "harmful" LDL cholesterol is high, and "protective" HDL cholesterol is low...
Detailed Description
Objective: To assess, in patients with coronary heart disease and low HDL-cholesterol, the efficacy and tolerability of Niaspan as an adjunct to statin therapy in clinical practice. Background: Despi...
Eligibility Criteria
Inclusion
- Persisting low HDL-C (\<0.9mmol/l) on a full lipid profile result (which for inpatients should have been taken \<24 hours after admission).
- Objective diagnosis of coronary heart disease (previous biomarker proven MI, positive stress test, angiogram with at least one \>50% diameter stenosis)
- Established for at least 6 weeks on a "maintenance" dose of statin therapy (defined as Pravastatin 40mg, Simvastatin 40mg or Atorvastatin ≥10mg). The dose and type of statin should not be altered during the study period
- Absence of concurrent major systemic illness (particularly liver or renal failure, or hypo or hyperthyroidism)
Exclusion
- Previous use of Niaspan or other non-statin lipid lowering agent within the previous 12 weeks
- Contraindications to Niaspan therapy
- Participation in another medical trial within the previous 30days
- Failure to obtain informed consent
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00238004
Start Date
November 1 2005
Last Update
September 13 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Craigavon Cardiac Centre
Craigavon, United Kingdom